Press Releases :: Nighthawk Biosciences, Inc. (NHWK)

Nov 05, 2019 8:00am EST

Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment

Oct 24, 2019 9:00am EDT

Heat Biologics Announces a Poster Presentation of Updated Top Line Phase 2 Data of HS-110 plus Nivolumab after Checkpoint Inhibitor Treatment Failure in NSCLC Patients at the SITC 34th Annual Meeting

Aug 14, 2019 7:00am EDT

Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update

Aug 12, 2019 7:00am EDT

Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heat’s HS-110

Aug 07, 2019 11:15am EDT

Heat Biologics CEO and Lead Director to Participate in German Investor Forums

Jul 09, 2019 8:00am EDT

Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial

Jun 03, 2019 6:55am EDT

Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

May 20, 2019 8:30am EDT

Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

May 15, 2019 7:30am EDT

Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update

May 06, 2019 7:00am EDT

Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai

rss_feed News RSS

OUR ECOSYSTEM